Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242317037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ichiro Kawahata und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan AMED.
Abstract (Originalsprache)
Parkinson’s disease is a neurodegenerative condition characterized by motor dysfunction resulting from the degeneration of dopamine-producing neurons in the midbrain. This dopamine deficiency gives rise to a spectrum of movement-related symptoms, including tremors, rigidity, and bradykinesia. While the precise etiology of Parkinson’s disease remains elusive, genetic mutations, protein aggregation, inflammatory processes, and oxidative stress are believed to contribute to its development. In this context, fatty acid-binding proteins (FABPs) in the central nervous system, FABP3, FABP5, and FABP7, impact α-synuclein aggregation, neurotoxicity, and neuroinflammation. These FABPs accumulate in mitochondria during neurodegeneration, disrupting their membrane potential and homeostasis. In particular, FABP3, abundant in nigrostriatal dopaminergic neurons, is responsible for α-synuclein propagation into neurons and intracellular accumulation, affecting the loss of mesencephalic tyrosine hydroxylase protein, a rate-limiting enzyme of dopamine biosynthesis. This review summarizes the characteristics of FABP family proteins and delves into the pathogenic significance of FABPs in the pathogenesis of Parkinson’s disease. Furthermore, it examines potential novel therapeutic targets and early diagnostic biomarkers for Parkinson’s disease and related neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
- BRI Pharma Inc., Sendai 982-0804, Japan.
ORCID-Profile: Ichiro Kawahata, Kohji Fukunaga
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Japan AMED
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Takeda Science Foundation
Zitieren
APA
Kawahata, I., & Fukunaga, K. (2023). Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242317037
Vancouver
Kawahata I, Fukunaga K. Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242317037
BibTeX
@article{Kawahata2023,
author = {Kawahata, Ichiro and Fukunaga, Kohji},
title = {Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242317037}
}
EUVIMED